This clinical trial is for patients with advanced pancreatic cancer, testing two treatments: **Ivaltinostat** and **Capecitabine**. Pancreatic adenocarcinoma is a type of cancer in the pancreas, an organ that helps with digestion. **Ivaltinostat** is a new drug being studied that may help treat this cancer. **Capecitabine** is an existing cancer medicine in pill form. The study has two phases. In Phase 1b, the study will determine the best dose of Ivaltinostat to use with Capecitabine. In Phase 2, patients will randomly receive either both drugs or just Capecitabine. Eligible participants must have had prior treatment with a specific chemotherapy called **FOLFIRINOX** without their disease getting worse. The study will check how well the tumor responds every 6 weeks. If you join, you'll need to visit the clinic regularly for treatment and check-ups.

• The study lasts several months with regular clinic visits.
• Participants receive either one or both medications.
• Safety and side effects will be closely monitored.